Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.

Wiedmeier-Nutor, Julia E.; Iqbal, Madiha; Rosenthal, Allison C.; Bezerra, Evandro D.; Garcia-Robledo, Juan Esteban; Bansal, Radhika; Johnston, Patrick B.; Hathcock, Matthew; Larsen, Jeremy T.; Leif Bergsagel, P.; Wang, Yucai; Reeder, Craig B.; Leis, Jose F.; Fonseca, Rafael; Palmer, Jeanne M.; Gysbers, Brianna J.; Mwangi, Raphael; Warsame, Rahma M.; Kourelis, Taxiarchis; Hayman, Suzanne R.

This study evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among non-Hodgkin lymphoma and multiple myeloma CAR T therapy recipients. In this retrospective study, we evaluated 104 patients that received CAR T therapy; of those 17 patients were evaluated for antibody spike titers following CAR T therapy. We found that only a minority of non-Hodgkin lymphoma and multiple myeloma patients were able to mount a clinically relevant (>250 IU/mL) antibody response. COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T. We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL).

Clinical Lymphoma, Myeloma & Leukemia, 2023, Vol 23, Issue 6, p456

2152-2650

Academic Journal

10.1016/j.clml.2023.03.002